Tianjin Eye Hospital

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Macular degeneration7 trials
• Glaucoma2 trials
• Diabetic eye disease1 trial
• High blood pressure1 trial

Phase

• Phase 36 trials
• Phase 22 trials
• Phase 41 trial

Status

• Active, not recruiting3 trials
• Completed3 trials
• Not yet recruiting2 trials
• Recruiting2 trials

Lead sponsor

• Bayer1 trial
• BioDlink Biopharm Co., Ltd.1 trial
• Hoffmann-La Roche1 trial
• Innostellar Biotherapeutics Co.,Ltd1 trial
• Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.1 trial
• and 5 more

Running trials

• Recruiting

  Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration

  NCT07776522· Phase 2· West China Hospital· Source

  Contact: Han

• Recruiting

  A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy

  NCT07777861· Phase 2· Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.· Source

  Contact: Shixiang Lu

• Recruiting

  Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

  NCT07317934· Phase 3· Innostellar Biotherapeutics Co.,Ltd· Source

  Contact: Principal Investigator

• Not yet recruiting

  A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)

  NCT07365371· Phase 4· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

  Contact: Mei Han

• Active, not recruiting

  A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

  NCT06666855· Phase 3· Santen Pharmaceutical Co., Ltd.· Source

• Active, not recruiting

  Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

  NCT06439576· Hoffmann-La Roche· Source

• Active, not recruiting

  TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration

  NCT05461339· Phase 3· BioDlink Biopharm Co., Ltd.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration3 recruiting
• Glaucoma1 recruiting

Closed trials

• Completed

  A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss

  NCT05520177· Phase 3· Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.· Source

• Completed

  Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

  NCT05003245· Phase 3· Shanghai Henlius Biotech· Source

• Completed

  Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

  NCT04423718· Phase 3· Bayer· Source